sfa 11:0

SFA 11:0, commonly known by its chemical name undecanoic acid (also called undecylic acid or hendecanoic acid), is a saturated fatty acid characterized by an 11‑carbon straight chain and no double bonds. As a member of the saturated fatty acid (SFA) family, it is part of the broad class of lipids that are solid at room temperature and typically found embedded in triglycerides and phospholipids in foods and biological tissues. Unlike more abundant even‑chain saturated fatty acids such as palmitic (C16:0) or stearic acid (C18:0), SFA 11:0 contains an odd number of carbon atoms, making it part of the so‑called odd‑chain fatty acids (OCFAs). OCFAs are present in trace amounts in human tissues and plasma and are derived from both dietary intake and de novo metabolic processes that use propionyl‑CoA as a primer instead of the typical acetyl‑CoA for fatty acid synthesis. The odd‑chain fatty acids like C11:0, while less studied, have distinct biochemical properties due to their metabolism producing propionyl‑CoA and succinyl‑CoA, intermediates that can feed into the citric acid cycle and gluconeogenesis. At the molecular level, undecanoic acid is a simple straight‑chain saturated fatty acid with the formula C11H22O2 and a molecular weight of approximately 186.29 g/mol. The compound is lipophilic and tends to integrate into lipid structures or be utilized as a free fatty acid substrate. SFA 11:0 occurs naturally in various foods, albeit in low quantities, particularly in the fat fraction of ruminant milk and dairy products, and in some plant oils such as coconut. Its presence is typically measured using gas chromatography or mass spectrometry techniques that can resolve individual fatty acid chains. From a nutritional perspective, there is no unique dietary requirement established for undecanoic acid itself; instead, nutrition guidance focuses on total saturated fat intake due to its influence on lipid profiles and cardiovascular risk. The compound has also been investigated in other contexts, for example as an antimicrobial agent, given its biochemical properties that disrupt microbial cell membranes at sufficient concentrations. However, typical dietary intakes are far below levels used in clinical or industrial applications. Despite its limited abundance in foods, SFA 11:0 illustrates the complexity of dietary fats and the nuanced roles different fatty acids play in human metabolism. It exemplifies an area where lipid biochemistry intersects with nutritional science: while total saturated fat has broad health implications, individual fatty acids within that category may have distinct metabolic fates and biological effects that are only now being elucidated with advanced analytical and omics methods.

SFA 11:0 participates in human metabolism primarily as a component of the complex lipid pool. Like other saturated fatty acids, it contributes to dietary energy intake: when ingested, triglycerides containing undecanoic acid are hydrolyzed by lipases, releasing free fatty acids that undergo beta‑oxidation to generate ATP. Because odd‑chain fatty acids yield propionyl‑CoA in their final cycle of beta‑oxidation, their metabolism diverges from even‑chain saturated fatty acids, which yield only acetyl‑CoA. The propionyl‑CoA can be converted into succinyl‑CoA, enabling anaplerotic entry into the citric acid cycle and potentially influencing gluconeogenesis in the liver. This metabolic nuance suggests that odd‑chain fatty acids including SFA 11:0 may contribute differently to energy homeostasis compared to their even‑chain counterparts. Beyond fundamental energy metabolism, research into odd‑chain saturated fatty acids has revealed associations with health outcomes. Emerging epidemiological data indicate that higher circulating levels of some odd‑chain fatty acids, specifically pentadecanoic (C15:0) and heptadecanoic (C17:0) acids, correlate with lower risk of cardiometabolic disease in observational cohorts. Although direct evidence for undecanoic acid is limited by its low abundance in plasma, it shares metabolic pathways with these related odd‑chain fatty acids, suggesting potential effects on lipid metabolism. It is important to recognize that these associations do not establish causality and that the bulk of evidence relates to composite biomarkers of dairy‑fat intake rather than isolated effects of the 11:0 chain. Some mechanistic studies have identified that medium‑chain SFAs can serve as ligands for specific G‑protein‑coupled receptors on immune cells, potentially modulating inflammatory pathways. For example, receptor GPR84 is activated by medium‑chain saturated free fatty acids, including C11:0, and this activation in immune cells can influence cytokine production and chemotactic responses through intracellular signaling cascades. These signaling interactions demonstrate that fatty acids can serve dual roles as nutrients and molecular signals with broader physiological influence. Moreover, a subset of odd‑chain fatty acids has been examined for potential bioactivity beyond basic lipid metabolism. In vitro studies have reported that odd‑chain fatty acids can interact with histone deacetylase pathways, showing inhibitory activity that may have relevance for cell proliferation and cancer biology. In these experimental settings, undecanoic acid exhibited inhibitory effects on HDAC6, although the physiological relevance of such findings at dietary exposure levels is not yet established. Thus, while SFA 11:0 does not have established health benefit claims as a standalone nutrient, current research into odd‑chain fatty acids encourages a deeper investigation of how individual lipid species may modulate metabolism and cell signaling.

Currently there are no official dietary intake recommendations for sfa 11:0 specifically, because it is not considered an essential nutrient with unique requirement. Instead, nutrition guidelines focus on the intake of total fat and saturated fatty acids collectively. The Dietary Guidelines for Americans and similar public health guidance recommend limiting saturated fat to less than 10% of total daily caloric intake in adults and children over age 2 to reduce the risk of cardiovascular disease. The U.S. Food and Drug Administration’s daily value for saturated fat used on Nutrition Facts labels is 20 grams per day for adults and children aged four years and older, based on a 2,000‑calorie diet. This benchmark includes all saturated fatty acids (e.g., palmitic, stearic, myristic, lauric, and minor odd‑chain species like C11:0) and is not specific to SFA 11:0. Because SFA 11:0 is present only in trace amounts relative to other more abundant saturated fatty acids, its contribution to total saturated fat intake is often minimal compared to more prevalent species. Nevertheless, dietary patterns rich in whole‑food sources of fats—like dairy, meats, and certain plant oils—will contribute small amounts of SFA 11:0 alongside other lipid species. Rather than targeting a specific amount of SFA 11:0, health professionals recommend prioritizing overall dietary patterns that balance fats: replace a portion of saturated fats with unsaturated fats where appropriate to improve lipid profiles, and emphasize nutrient‑dense foods that fit within caloric needs. In populations with certain medical conditions such as dyslipidemia, diabetes, or established cardiovascular disease, even lower saturated fat targets (e.g., 5–6% of calories) may be advised as part of a comprehensive dietary strategy. The lack of a specific recommendation for SFA 11:0 highlights the broader principle that individual fatty acids within the saturated category are assessed in aggregate for public health guidance, with the focus on modulating overall lipid intake based on evidence linking saturated fat to LDL cholesterol and cardiovascular risk.

Because sfa 11:0 is not an essential nutrient with unique physiological requirement, there are no recognized deficiency symptoms attributable to its absence alone. Rather, deficiency concerns pertain to inadequate total fat intake or essential fatty acid deficiency, which involves shortages of linoleic acid (omega‑6) and alpha‑linolenic acid (omega‑3) rather than saturated fatty acids. Essential fatty acid deficiency manifests with symptoms such as scaly dermatitis, alopecia, poor wound healing, and impaired growth in infants due to disrupted cell membrane integrity and impaired synthesis of eicosanoids. Individuals with severely restricted diets, malabsorption syndromes, or prolonged parenteral nutrition without adequate lipid provision are at risk for general fat and essential fatty acid deficiencies. SFA 11:0 itself does not have specific clinical sequelae associated with low intake, as it constitutes a minor component of the overall lipid pool and can be synthesized or replaced by other fatty acids in metabolic pathways. Instead, health concerns focus on meeting adequate total fat and essential fatty acid requirements to maintain membrane structure, energy balance, and hormone synthesis.